Latest non-small cell lung cancer Stories
CYRAMZA is the first treatment approved in the U.S. for use in combination with docetaxel in second-line metastatic non-small cell lung cancer INDIANAPOLIS, Dec.
- "Any One Any Lung" survey shows nearly six in 10 adults are unaware that lung cancer is responsible for most cancer-related deaths worldwide(1) EAST HANOVER, N.J., Nov.
DelMar Pharmaceuticals Presents Data at AACR's New Horizons in Cancer Research Conference in Shanghai, China VANCOUVER, British Columbia, MENLO PARK, Calif. and SHANGHAI, Oct.
- AbbVie presents preliminary data from randomized phase 2 trial of veliparib in non-small cell lung cancer NORTH CHICAGO, Ill., Sept.
LUGANO, Switzerland, September 27, 2014 /PRNewswire/ -- The Helsinn Group, a Company focused on building quality cancer care, announces that anamorelin, its novel, once-daily
Presentations include first Phase 2 results evaluating investigational compound Veliparib in patients with non-small cell lung cancer NORTH CHICAGO, Ill., Sept.
LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).
-- REVEL Data Published in The Lancet, Presented at Annual ASCO Meeting -- CHICAGO, June 2, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from REVEL,
- Ceritinib achieved overall response rate of 58.5%, with a median progression-free survival of 8.2 months1 EAST HANOVER, N.J., June 2, 2014 /PRNewswire/ -- Novartis today announced data showing
- totally perplexed and mixed up.